Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...

I just felt I could do so much more. And I really do credit NAD for it.” Camilla Thompson credits the NAD molecule for her improved functioning.Credit: Syl Marie NAD – Nicotinamide adenine ...

2021 Blenrep (belantamab mafodotin-blmf) Adults patients with R/R MM who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an ...

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even the ...

GSK unveiled encouraging results from its ‘DREAMM-8’ phase three trial on Thursday, comparing the efficacy of ‘Blenrep’, or belantamab mafodotin, in combination with pomalidomide plus ...